Phibro Animal Health Corp (PAHC) (Q1 2027) Earnings Call Highlights: Solid Start to Fiscal
Phibro Animal Health (PAHC) reported Q1 2027 sales of $386.8M (+6%) and adjusted EBITDA of $64.3M (+4%). CEO Donnie Bantine expects Brazil Virginiamycin approval but no sales assumed in 2027. Zoetis portfolio drove MFA growth, while livestock margins are squeezed. USDA's border reopening impacts cattle imports. Net income rose 11% to $29.5M. Guidance remains unchanged, with net sales expected between $1.55B-$1.6B.
How this was made
The 30-second read
Why it matters
The disclosed numbers and guidance are new information that can affect PAHC's stock price and sector sentiment.
Market read
First‑time earnings and guidance release for PAHC, providing actionable data for traders.
What to watch
Higher feed and fuel costs could compress margins despite revenue growth.
Background
Phibro Animal Health Corp held its Q1 fiscal 2027 earnings call, providing detailed financial results and outlook.
Ticker impact
Q1 fiscal 2027 sales of $386.8M, adjusted EBITDA $64.3M and guidance of $1.55‑$1.6B net sales were disclosed for the first time.
potential upside as market prices in higher‑than‑expected sales and EBITDA guidance
The company reported better‑than‑expected growth and raised full‑year sales guidance, which typically drives buying pressure.
Market effects
Positive signal for animal health and livestock nutrition sector, may boost peers.
U.S. agribusiness investors could see increased interest.
Limited to specialty agriculture markets; no broad macro effect.
Counterpoint
Guidance assumes no Brazil sales; any delay in Virginiamycin approval could pressure earnings.
Key entities
- companyPhibro Animal Health Corp
Animal health and nutrition company reporting Q1 results.
- executiveDonnie Bantine
CEO who discussed sales growth and Brazil regulatory outlook.
